You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday.
Akili SPAC deal could close soon
Nearly seven months after therapeutic video game maker Akili Interactive announced plans to go public via a merger with a special purpose acquisition company, the deal may be on the verge of closing. The shareholders of Social Capital Suvretta Holdings Corp. I, one of several SPACs helmed by former Facebook exec Chamath Palihapitiya, are meeting today to discuss the proposed merger with Akili. It’s possible that Akili could start trading as early as next week if the final vote clears. The deal would yield Akili at least $162 million in proceeds to fuel the launch of EndeavorRx, Akili’s FDA-cleared game for the treatment of childhood ADHD. That number could go as high as $400 million depending on how many of the SPAC’s shareholders decide to withdraw their money.
Create a display name to comment
This name will appear with your comment
